Lower riskDrug recall · FDA · Published July 29, 2019
Upsher Smith Bexarotene Capsules Recall: Failed Dissolution Specifications
Upsher Smith recalls 75mg Bexarotene Capsules due to failed dissolution specifications. Rx-only capsules may not release medication properly. Contact for return instructions.
“Upsher Smith Bexarotene Capsules Recall: Failed Dissolution Specifications.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/38200-upsher-smith-bexarotene-capsules-recall-failed-dissolution-specifications. Based on FDA recall #D-1836-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1836-2019%22&limit=1).
Upsher Smith Laboratories, Inc. voluntarily recalled Bexarotene Capsules, 75 mg, due to failed dissolution specifications, the Food and Drug Administration said on July 29, 2019. The recall involves 166 bottles distributed in Kentucky, Ohio, New Jersey, and Louisiana.
How to tell if you have it
Brand: Upsher Smith
Product: Bexarotene Capsules, 75 mg, 100 capsules per bottle
NDC: 0832-0285-00
Lot: A2610
Expiration: 3/2020
Distribution: KY, OH, NJ, LA
The hazard
The product failed to meet dissolution specifications. The FDA classified the recall as Class II.
Context
GovInfoNow's records show Upsher Smith Laboratories, Inc. has had four other recalls since November 20, 2012. Other recent recalls of similar products include Supernus Trokendi XR 50mg Capsules (August 31, 2026), Sun Pharmaceutical Lisdexamfetamine Capsules (October 28, 2025), and AvKARE Amantadine Capsules (February 13, 2026).
How to tell if you have this one
Check for the product name 'Bexarotene Capsules', 75 mg, 100 capsules per bottle, Rx only. Look for NDC code 0832-0285-00 and lot number A2610 on the packaging.
Brand
Upsher Smith
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Verify the product name, strength, and packaging details to confirm if it matches the recalled items.
Contact Manufacturer
Reach out to Upsher Smith Laboratories for specific return or disposal instructions.
Where it went and when
Where it was distributed
Distributed in 4 states.
Listed by the agency
Not listed
FDA distribution: “KY, OH, NJ, LA” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: Kentucky, Louisiana, New Jersey, Ohio.
Recall timeline
FDA terminated this recall 3.1 years after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-1836-2019 (July 29, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1836-2019 to see it in context.
Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.